Effective activism can
Founded in March 2018, PrEP4All is an organization of community members, healthcare professionals, lawyers, and academics all dedicated to increasing access to lifesaving HIV medication. Every member of PrEP4All has been personally affected by the HIV epidemic, and most of us rely on HIV medications every day. As patients ourselves, we have all experienced the shortcomings in the domestic HIV response first hand, whether through arguing with insurance companies refusing to cover our medication, encountering doctors unwilling to refill our prescriptions, or receiving an unexpected bill for $1,800 after our copay assistance has run out. Our biggest strength is our personal experience.
In the tradition of activism blazed by ACT UP in the 1980s, PrEP4All uses direct action, media, and political advocacy to lower the price of PrEP and ensure universal access to HIV prevention and treatment.
In 2019, the U.S. government set a goal to reduce annual HIV infections by 90% by 2030. Despite this, a new person in the U.S. is diagnosed with HIV every 15 minutes. More often than not, that person is LGBTQ+, low-income, and a person of color. Meanwhile, Gilead Sciences, the first manufacturer of PrEP, charges up to $2,000 a month for the drug despite it costing less than $6 per month in other countries. Gilead’s profiteering has hamstrung the HIV response in the U.S., despite PrEP being a government-funded invention.
Biden Administration included funding for PrEP For All To End The HIV Epidemic program in FY 2023 budget after PrEP4All released white paper outlining implementation recommendations for a federally-funded national PrEP program.
Working with a team from NYU Law School, we released a user’s guide to government patent use for the new Biden administration to take on lowering drug prices.
We drew 250,000+ participants to a virtual event with experts and policymakers to call on the Trump Administration to intervene and end remdesivir shortages.
We organized a U.S. Congressional Committee on Oversight and Reform hearing where representatives questioned Gilead’s CEO bout the company’s price gouging.